Stockscreener 앱 받기
61.39
1.35%
0.82
시간 외 거래:
62.40
1.01
+1.65%
전일 마감가:
$60.57
열려 있는:
$61
하루 거래량:
14.73M
Relative Volume:
1.35
시가총액:
$125.40B
수익:
$48.48B
순이익/손실:
$7.27B
주가수익비율:
17.23
EPS:
3.5626
순현금흐름:
$11.91B
1주 성능:
-2.56%
1개월 성능:
-2.34%
6개월 성능:
+6.60%
1년 성능:
+44.11%
1일 변동 폭
$60.00
$61.56
1주일 범위
$60.00
$62.84
52주 변동 폭
$42.52
$68.64
브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile
명칭
Bristol Myers Squibb Co
전화
(609) 252-4621
주소
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
61.39 | 125.40B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,373.70 | 1.22T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
275.20 | 662.49B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
290.79 | 513.86B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
146.33 | 361.02B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
161.10 | 304.26B | 54.66B | 13.58B | 16.05B | 7.0171 |
브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2026-08-05 | 업그레이드 | Argus | Hold → Buy |
| 2026-02-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-12-12 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 개시 | Piper Sandler | Overweight |
| 2024-12-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-13 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-07-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2024-02-06 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-07-10 | 개시 | SVB Securities | Market Perform |
| 2023-06-28 | 개시 | Daiwa Securities | Outperform |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-01-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 개시 | Credit Suisse | Neutral |
| 2022-10-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-06-03 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Underweight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-01 | 다운그레이드 | Argus | Buy → Hold |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | 업그레이드 | Truist | Hold → Buy |
| 2020-11-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-11-06 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2020-10-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-07-28 | 개시 | Raymond James | Outperform |
| 2020-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-06 | 재개 | Citigroup | Buy |
| 2019-12-13 | 업그레이드 | Argus | Hold → Buy |
| 2019-11-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-08-14 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2019-05-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 재개 | JP Morgan | Overweight |
| 2019-01-15 | 업그레이드 | Societe Generale | Sell → Buy |
| 2018-10-22 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스
BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook - Zacks Investment Research
Bristol Myers Squibb beats forecasts and nudges up sales outlook - MedWatch
Bristol Myers Raises Sales Guidance on Demand For New Drugs - Bloomberg.com
Bristol Myers lifts sales outlook as newer medicines grow - The Pharma Letter
Bristol-Myers Squibb Q3 2026 Earnings Call Transcript - Benzinga
Bristol Myers Squibb (BMY) Raises 2026 Revenue Outlook After Str - GuruFocus
Bristol-Myers Squibb Reports Q3 2026 Revenue of $13.1 Billion an - GuruFocus
BRISTOL-MYERS SQUIBB ($BMY) Releases Q3 2026 Earnings - Quiver Quantitative
Bristol Myers Squibb Reports Third Quarter Financial Results for 2026 - Finviz
Form 8-K BRISTOL MYERS SQUIBB CO For: Oct 29 - StreetInsider
Bristol Myers: Q3 Earnings Snapshot - kare11.com
86,136 Bristol Myers Squibb Company $BMY Shares Sold by Conning Inc. - MarketBeat
Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight - GlobeNewswire Inc.
Bristol-Myers Squibb earnings loom as pipeline takes center stage - Investing.com
Pathos raises $237M and lands Alzheimer’s drug deal with Tempus, Bristol Myers - Crain's Chicago Business
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? - The Motley Fool
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings? - Zacks Investment Research
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings? - TradingView
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy? - Zacks Investment Research
Bristol Myers Squibb’s Cancer Drug Just Doubled Survival Time Without Progression — Here’s Why It Matters - The Motley Fool
3 Cheap Dividend Stocks I'd Buy Without Any Hesitation - The Motley Fool
Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings? - Zacks Investment Research
Bristol-Myers Squibb (NYSE:BMY): Weighing Dividend Quality for Income Investors - ChartMill
Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study - BioSpace
Bristol Myers Iza-Bren Phase 3 PFS Reaches 11.1 Months - grafa.com
Breakfast News: Science Strikes Back at Cancer - The Motley Fool
Pathos AI Raises $237M at $3B Valuation in Round Led by Bristol Myers Squibb - citybiz
3 High-Yield Stocks to Buy With $1,000 Right Now - The Motley Fool
Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings? - The Motley Fool
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy - GlobeNewswire Inc.
BioNTech und Bristol Myers Squibb präsentieren ermutigende Daten aus globaler Phase-2-Studie mit Pumitamig bei fortgeschrittenem nicht-kleinzelligem Lungenkrebs nach Progression der Erkrankung unter einer Immuntherapie und Chemotherapie - GlobeNewswire Inc.
Bristol Myers Squibb Co. CDR Overview (BMY) - Barron's
Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? - The Motley Fool
Patient dies in Bristol Myers Squibb autoimmune CAR-T trial - STAT
Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Zacks Investment Research
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Bristol Myers discloses patient death in early-stage cell therapy study - Reuters
What's Going On with Bristol Myers Squibb Stock on Friday? - Benzinga
Bristol Myers Reports CAR-T Death as Safety Concerns Mount - Bloomberg.com
Bristol-Myers Squibb Co: Following Data Cutof - Moomoo
BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential? - Zacks Investment Research
Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development - Reuters
Bristol Myers, SystImmune breast cancer drug cuts progression risk in study - Reuters
Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb? - The Motley Fool
Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb? - The Motley Fool
Bristol-Myers Squibb Company (BMY) Options ChainYahoo Finance - Yahoo! Finance Canada
IHI and Bristol Myers Squibb Launch National Collaborative to Expand Access to Cancer Clinical Trials - BioSpace
A Look at Bristol-Myers Squibb Co (BMY) After 3.1% Gain -- GF Va - GuruFocus
Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue - The Motley Fool
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
브리스톨 마이어스 스퀴브 (BMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
브리스톨 마이어스 스퀴브 주식 (BMY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Massacesi Cristian | EVP,Chief Med Offr,Head of Dev |
Sep 09 '26 |
Sale |
64.57 |
6,249 |
403,498 |
18,748 |
| Massacesi Cristian | Officer |
Sep 09 '26 |
Proposed Sale |
64.57 |
6,249 |
403,498 |
0 |
| Short Bartie Wendy | EVP, Corporate Affairs |
Sep 01 '26 |
Option Exercise |
66.92 |
1,236 |
82,713 |
13,317 |
| Holzer Phil M | Officer |
Aug 25 '26 |
Proposed Sale |
67.50 |
500 |
33,750 |
0 |
| Holzer Phil M | SVP and Controller |
Aug 25 '26 |
Sale |
67.50 |
500 |
33,750 |
16,862 |
| Gallman Cari | EVP, General Counsel |
Aug 01 '26 |
Option Exercise |
0.00 |
1,061 |
0 |
14,192 |
| Massacesi Cristian | EVP,Chief Med Offr,Head of Dev |
Aug 01 '26 |
Option Exercise |
0.00 |
51,172 |
0 |
51,172 |
| Haller Julia A | Director |
Jun 15 '26 |
Option Exercise |
53.76 |
20,460 |
1,099,930 |
34,079 |
| Short Bartie Wendy | EVP, Corporate Affairs |
Jun 03 '26 |
Option Exercise |
0.00 |
8,040 |
0 |
15,957 |
| Lenkowsky Adam | EVP, Chief Commercial Officer |
May 01 '26 |
Option Exercise |
0.00 |
1,373 |
0 |
20,508 |
2.11%
0.12%
자본화:
|
볼륨(24시간):